[1]
|
F. I. Alamdari, T. Rasmuson, K. Grankvist, et al., “Angiogenesis and Other Markers for Prediction of Survival in Metastatic Renal Cell Carcinoma,” Scandinavian Journal of Urology and Nephrology, Vol. 41, No. 1, 2007, pp. 5-9.
|
[2]
|
L. Glouchkova, B. Ackermann and D. Dilloo, “Leukemia Vaccines,” Acta Haematologica, Vol. 110, No. 4, 2003, pp. 160-170.
|
[3]
|
M. Robin, M. H. Schlageter, C. Chomienne, et al., “Targeted Immunotherapy in Acute Myeloblastic Leukemia: From Animals to Humans,” Cancer Immunology and Immunotherapy, Vol. 54, No. 10, 2005, pp. 933-943.
|
[4]
|
I. M. Borrello and E. M. Sotomayor, “Cancer Vaccines for Hematologic Malignancies,” Cancer Control, Vol. 9, No. 2, 2002, pp. 138-151.
|
[5]
|
J. Gong, D. Avigan, D. Chen, et al., “Activation of Antitumor Cytotoxic T Lymphocytes by Fusions of Human Dendritic Cells and Breast Carcinoma Cells,” Proceedings of National Academy Sciences, Vol. 97, No. 6, 2000(a), pp. 2715-2718.
|
[6]
|
J. Gong, D. Chen, M. Kashiwaba, et al., “Induction of
Antitumor Activity by Immunization with Fusions of Dendritic and Carcinoma Cells,” Nature Medicine, Vol. 3, No. 4, 1997, pp. 558-561.
|
[7]
|
M. Klammer, M. Waterfall, K. Samuel, et al., “Fusion Hybrids of Dendritic Cells and Autologous Myeloid Blasts as a Potential Cellular Vaccine for Acute Myeloid Leukaemia,” British Journal of Haematology, Vol. 129, No. 3, 2005, pp. 340-349.
|
[8]
|
R. Ridolfi, L. Ridolfi, M. Petrini, L. Fiammenghi and A. Riccobon, “Dendritic Cell Vaccination and Immunosti- mulation in Advanced Melanoma,” Expert Review of Vaccines, Vol. 2, No. 6, 2003, pp. 825-833.
|
[9]
|
Y. Becker, “Immunological and Regulatory Functions of Uninfected and Virus Infected Immature and Mature Subtypes of Dendritic Cells - A Review,” Virus Genes, Vol. 26, No. 2, 2003, pp. 119-130.
|
[10]
|
R. Stripecke, A. M. Levine, V. Pullarkat, et al., “Immunotherapy with Acute Leukemia Cells Modified into Antigen-Presenting Cells: Ex vivo Culture and Gene Transfer Methods,” Leukemia, Vol. 16, No. 10, 2002, pp. 1974- 1983.
|
[11]
|
R. A. Willemsen, C. Ronteltap, P. Chames, et al., “T Cell Retargeting with MHC Class I-Restricted Antibodies: The CD28 Costimulatory Domain Enhances Antigen- Specific Cytotoxicity and Cytokine Production,” Journal of Immunology, Vol. 174, No. 12, 2005, pp. 7853-7858.
|
[12]
|
E. Ranieri, M. Gigante, W. J. Storkus, et al., “Translational Mini-Review Series on Vaccines: Dendritic Cell- based Vaccines in Renal Cancer,” Clinical and Experimental Immunology, Vol. 147, No. 3, 2007, pp. 395-400.
|
[13]
|
J. Galea-Lauri, D. Darling, G. Mufti, et al., “Eliciting Cytotoxic T Lymphocytes against Acute Myeloid Leukemia-Derived Antigens: Evaluation of Dendritic Cell- Leukemia Cell Hybrids and Other Antigen-Loading Strategies for Dendritic Cell-Based Vaccination,” Cancer Immunology and Immunotherapy, Vol. 51, 2002, pp. 299-310.
|
[14]
|
W. Herr, E. Ranieri, W. Olson, et al., “Mature Dendritic Cells Pulsed with Freeze-Thaw Cell Lysates Define an Effective in Vitro Vaccine Designed to Elicit EBV-Specific CD4(+) and CD8(+) T Lymphocyte Responses,” Blood, Vol. 96, No. 5, 2000, pp. 1857-1864.
|
[15]
|
J. J. Lee, C. E. Nam, J. H. Nam, et al., “Generation of Cytotoxic Donor CD8+ T Cells against Relapsing Leukemic Cells Following Allogeneic Transplantation by Stimulation with Leukemic Cell- or Leukemic Lysate Pulsed Donor Cell-Derived Dendritic Cells,” Leukemia Research, Vol. 28, No. 5, 2004, pp. 517-524.
|
[16]
|
Y. Liu, W. Zhang, T. Chan, et al., “Engineered Fusion Hybrid Vaccine of IL-4 Gene-Modified Myeloma and Relative Mature Dendritic Cells Enhances Antitumor Immunity,” Leukemia Research, Vol. 26, No. 8, 2002, pp. 757-763.
|
[17]
|
D. Montagna, R. Maccario, E. Montini, et al., “Generation and Ex vivo Expansion of Cytotoxic T Lymphocytes Directed toward Different Types of Leukemia or Myelodysplastic Cells Using both HLA-Matched and Partially Matched Donors,” Experimental Hematology, Vol. 31, No. 11, 2003, pp. 1031-1038.
|
[18]
|
W. Song, H. L. Kong, H. Carpenter, et al., “Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for a Model Antigen Induce Protective and Therapeutic Antitumor Immunity,” Journal of Experimental Medicine, Vol. 186, No. 8, 1997, pp. 1247- 1256.
|
[19]
|
D. Avigan, “Dendritic Cells: Development, Function and Potential Use for Cancer Immunotherapy,” Blood Review, Vol. 13, No. 1, 1999, pp. 51-64.
|
[20]
|
J. Gong, N. Nikrui, D. Chen, et al., “Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity,” Journal of Immunology, Vol. 165, No. 3, 2000(b), pp. 1705-1711.
|
[21]
|
A. Nencioni and P. Brossart, “Cellular Immunotherapy with Dendritic Cells in Cancer: Current Status,” Stem Cells, Vol. 22, No. 4, 2004, pp. 501-513.
|
[22]
|
S. W. Krause, C. Neumann, A. Soruri, et al., “The Treatment of Patients with Disseminated Malignant Melanoma by Vaccination with Autologous Cell Hybrids of Tumor Cells and Dendritic Cells,” Journal of Immunotherapy, Vol. 25, No. 5, 2002, pp. 421-428.
|
[23]
|
D. K. Schui, L. Singh, B. Schneider, et al., “Inhibiting Effects on the Induction of Cytotoxic T Lymphocytes by Dendritic Cells Pulsed with Lysates from Acute Myeloid Leukemia Blasts,” Leukemia Research, Vol. 26, No. 4, 2002, pp. 383-389.
|
[24]
|
L. M. Faber, S. A. van Luxemburg-Heijs, W. F. Veenhof, et al., “Generation of CD4+ Cytotoxic T-Lymphocyte Clones from a Patient with Severe Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation: Implications for Graft-Versus-Leukemia Reactivity,” Blood, Vol. 86, No. 7, 1995, pp. 2821-2828.
|
[25]
|
H. J. Kolb, J. Mittermuller, C. Clemm, et al., “Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients,” Blood, Vol. 76, No. 12, 1990, pp. 2462-2465.
|
[26]
|
P. A. McSweeney, D. Niederwieser, J. A. Shizuru, et al., “Hematopoietic Cell Transplantation in Older Patients with Hematologic Malignancies: Replacing High-Dose Cytotoxic Therapy with Graft-Versus-Tumor Effects,” Blood, Vol. 97, No. 11, 2001, pp. 3390-3400.
|
[27]
|
T. Mutis, R. Verdijk, E. Schrama, et al., “Feasibility of Immunotherapy of Relapsed Leukemia with Ex Vivo- Generated Cytotoxic T Lymphocytes Specific for Hematopoietic System-Restricted Minor Histocompatibility Antigens,” Blood, Vol. 93, No. 7, 1999, pp. 2336-2341.
|
[28]
|
E. Naparstek, A. Nagler, R. Or, et al., “Allogeneic Cell- mediated Immunotherapy Using Donor Lymphocytes for Prevention of Relapse in Patients Treated with Allogeneic Bone Marrow Transplantation for Hematological Malignancies,” Clinical Transplantation, 1996, pp. 281-290.
|
[29]
|
E. Naparstek, R. Or, A. Nagler, et al., “T-Cell-Depleted Allogeneic Bone Marrow Transplantation for Acute Leukaemia Using Campath-1 Antibodies and Post-Transplant Administration of Donor’s Peripheral Blood Lymphocytes for Prevention of Relapse,” British Journal of Haematology, Vol. 89, No. 3, 1995, pp. 506-515.
|
[30]
|
S. Slavin, E. Naparstek, A. Nagler, et al., “Allogeneic Cell Therapy with Donor Peripheral Blood Cells and Recombinant Human Interleukin-2 to Treat Leukemia Relapse after Allogeneic Bone Marrow Transplantation,” Blood, Vol. 87, No. 6, 1996(a), pp. 2195-2204.
|
[31]
|
S. Slavin, E. Naparstek, A. Nagler, et al., “Allogeneic Cell Therapy: The Treatment of Choice for All Hematologic Malignancies Relapsing Post BMT,” Blood, Vol. 87, No. 9, 1996(b), pp. 4011-4013.
|
[32]
|
R. J. Soiffer, “Donor Lymphocyte Infusions for Acute Myeloid Leukaemia,” Best Practice & Research Clinical Haematology, Vol. 21, No. 3, 2008, pp. 455-466.
|
[33]
|
M. Di Nicola, R. Zappasodi, C. Carlo-Stella, et al., “Vaccination with Autologous Tumor-Loaded Dendritic Cells Induces Clinical and Immunologic Responses in Indolent B-Cell Lymphoma Patients with Relapsed and Measurable Disease: A Pilot Study,” Blood, Vol. 113, No. 1, 2009, pp. 18-27.
|
[34]
|
B. Vasir, V. Borges, Z. Wu, et al., “Fusion of Dendritic Cells with Multiple Myeloma Cells Results in Maturation and Enhanced Antigen Presentation,” British Journal of Haematology, Vol. 129, No. 5, 2005, pp. 687-700.
|
[35]
|
J. O. Cullis, Y. Z. Jiang, A. P. Schwarer, et al., “Donor Leukocyte Infusions for Chronic Myeloid Leukemia in Relapse after Allogeneic Bone Marrow Transplantation,” Blood, Vol. 79, No. 5, 1992, pp. 1379-1381.
|
[36]
|
W. R. Drobyski, C. A. Keever, M. S. Roth, et al., “Salvage Immunotherapy Using Donor Leukocyte Infusions as Treatment for Relapsed Chronic Myelogenous Leukemia after Allogeneic Bone Marrow Transplantation: Efficacy and Toxicity of a Defined T-Cell Dose,” Blood, Vol. 82, No. 8, 1993, pp. 2310-2318.
|
[37]
|
D. L. Porter, M. S. Roth, S. J. Lee, et al., “Adoptive Immunotherapy with Donor Mononuclear Cell Infusions to Treat Relapse of Acute Leukemia or Myelodysplasia after Allogeneic Bone Marrow Transplantation,” Bone Marrow Transplant, Vol. 18, No. 16, 1996, pp. 975-980.
|
[38]
|
R. Ivanov, A. Hagenbeek and S. Ebeling, “Towards Immunogene Therapy of Hematological Malignancies,” Experimental Hematology, Vol. 34, No. 3, 2006, pp. 251- 263.
|
[39]
|
B. D. Johnson, E. E. Becker and R. L. Truitt, “Graft- vs.-Host and Graft-vs.-Leukemia Reactions after Delayed Infusions of Donor T-Subsets,” Biology of Blood and Marrow Transplantation, Vol. 5, No. 3, 1999, pp. 123-132.
|
[40]
|
G. Xia, R. L. Truitt and B. D. Johnson, “Graft-versus- Leukemia and Graft-versus-Host Reactions after Donor Lymphocyte Infusion are Initiated by Host-Type Antigen-Presenting Cells and Regulated by Regulatory T Cells in Early and Long-Term Chimeras,” Biology of Blood and Marrow Transplantation, Vol. 12, No. 4, 2006, pp. 397- 407.
|
[41]
|
E. P. Alyea, C. Canning, D. Neuberg, et al., “CD8+ Cell Depletion of Donor Lymphocyte Infusions Using CD8 Monoclonal Antibody-Coated High-Density Microparticles (CD8-HDM) after Allogeneic Hematopoietic Stem Cell Transplantation: A Pilot Study,” Bone Marrow Tran- splant, Vol. 34, No. 2, 2004, pp. 123-128.
|
[42]
|
R. J. Soiffer, E. P. Alyea, E. Hochberg, et al., “Randomized Trial of CD8+ T-Cell Depletion in the Prevention of Graft-versus-Host Disease Associated with Donor Lymphocyte Infusion,” Biology of Blood and Marrow Transplantation, Vol. 8, No. 11, 2002, pp. 625-632.
|
[43]
|
D. L. Porter, B. L. Levine, N. Bunin, et al., “A Phase 1 Trial of Donor Lymphocyte Infusions Expanded and Activated ex vivo via CD3/CD28 Costimulation,” Blood, Vol. 107, No. 4, 2006, pp. 1325-1331.
|
[44]
|
C. Bonini, G. Ferrari, S. Verzeletti, et al., “HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-versus-Leukemia,” Science, Vol. 276, No. 5391, 1997, pp. 1719-1724.
|
[45]
|
K. C. Hsu, C. A. Keever-Taylor, A. Wilton, et al., “Improved Outcome in HLA-Identical Sibling Hematopoietic Stem-Cell Transplantation for Acute Myelogenous Leukemia Predicted by KIR and HLA Genotypes,” Blood, Vol. 105, No. 12, 2005, pp. 4878-4884.
|
[46]
|
L. Ruggeri, M. Capanni, E. Urbani, et al., “Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatch- ed Hematopoietic Transplants,” Science, Vol. 295, No. 5562, 2002, pp. 2097-2100.
|
[47]
|
B. Carlsson, W. S. Cheng, T. H. Totterman, et al., “Ex vivo Stimulation of Cytomegalovirus (CMV)-Specific T Cells Using CMV pp65-Modified Dendritic Cells as Stimulators,” British Journal of Haematology, Vol. 121, No. 3, 2003, pp. 428-438.
|
[48]
|
S. El Marsafy and M. Bagot, A. Bensussan, et al., “Dendritic Cells in the Skin-Potential Use for Melanoma Treatment,” Pigment Cell and Melanoma Research, Vol. 22, No. 1, 2009, pp. 30-41.
|
[49]
|
T. J. Lehrfeld, D. I. Lee, “Dendritic Cell Vaccines for the Treatment of Prostate Cancer,” Urology and Nephrology, Vol. 26, No. 1, 2008, pp. 576-580.
|
[50]
|
J. H. Falkenburg, “Immunotherapy of Hematological Malignancies with Dendritic Cells,” Hematology Journal, Vol. 5, No. (Suppl. 3), 2004, pp. S96-S99.
|
[51]
|
W. Guo, Y. Guo, S. Tang, et al., “Dendritic Cell-Ewing’s Sarcoma Cell Hybrids Enhance Antitumor Immunity,” Clinical Orthopaedics and Related Research, Vol. 466, No. 9, 2008, pp. 2176-2183.
|
[52]
|
K. Imura, Y. Ueda, T. Hayashi, et al., “Induction of Cytotoxic T Lymphocytes against Human Cancer Cell Lines Using Dendritic Cell-Tumor Cell Hybrids Generated by a Newly Developed Electrofusion Technique,” International Journal of Oncology, Vol. 29, No. 3, 2006, pp. 531-539.
|
[53]
|
R. Savai, R. T. Schermuly, S. S. Pullamsetti, et al., “A Combination Hybrid-Based Vaccination/Adoptive Cellular Therapy to Prevent Tumor Growth by Involvement of T Cells,” Cancer Research, Vol. 67, No. 11, 2007, pp. 5443-5453.
|
[54]
|
T. Yasuda, T. Kamigaki, T. Nakamura, et al., “Dendritic Cell-Tumor Cell Hybrids Enhance the Induction of Cytotoxic T Lymphocytes against Murine Colon Cancer: A Comparative Analysis of Antigen Loading Methods for the Vaccination of Immunotherapeutic Dendritic Cells,” Oncology Reports, Vol. 16, No. 6, 2006, pp. 1317-1324.
|
[55]
|
J. H. Falkenburg, A. R. Wafelman, P. Joosten, et al., “Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by Treatment with Leukemia-Reac- tive Cytotoxic T Lymphocytes,” Blood, Vol. 94, No. 4, 1999, pp. 1201-1208.
|
[56]
|
D. Avigan, B. Vasir, J. Gong, et al., “Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses,” Clin Cancer Research, Vol. 10, No. 14, 2004, pp. 4699-4708.
|
[57]
|
S. Shu, R. Zheng, W. T. Lee, et al., “Immunogenicity of Dendritic-Tumor Fusion Hybrids and their Utility in Cancer Immunotherapy,” Critical Reviews in Immunology, Vol. 27, No. 5, 2007, pp. 463-483.
|